T1 stage breast cancer: Adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients - Pilot feasibility study

Radiology

Volumn 222, Issue 1, 2002, Pages 171-178

  Formenti, S C ^a   Rosenstein, B ^a   Skinner, K A ^a   Jozsef, G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms; Breast neoplasms, therapeutic radiology; Breast, CT; Computed tomography (CT), treatment planning

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ESTHETIC SURGERY; FEMALE; FOLLOW UP; HUMAN; LINEAR ACCELERATOR; MASTECTOMY; PATIENT POSITIONING; POSTMENOPAUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 0036135422     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2221010769     Document Type: Article

References (50)

1. Breast cancer treatment and natural history: New insight from results of screening
2. Update of the Swedish two-county program of mammographic screening for breast cancer
3. Non-palpable lesions of the breast detected by mammography: Review of 1182 consecutive histologically confirmed cases
4. Recent results from the Swedish Two-County Trial: The effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening
5. Commission of the European Communities "Europe Against Cancer" programme: European School of Oncology Advisory report - Management of non-palpable and small lesions found in mass breast screening
6. Radiation therapy in early stage breast cancer: Biologic and clinical rationale
7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
8. Factors influencing local recurrence of cancer after partial mastectomy
9. Re-analysis and results after 12 years of follow up in a randomized clinical trial comparing mastectomy with lumpectomy with and without radiation in the treatment of breast cancer
10. Histological multifocality of TIS, T1-2 breast carcinomas: Implications for clinical trials of breast-conserving surgery
11. The role of radiotherapy and tamoxifen in the management of node negative invasive breast cancer <1.0 cm treated with lumpectomy: Preliminary results of NSABP Protocol B-21
12. Invasive breast cancer in women age 75 and older
13. The use of a specific hypo-fractionated radiation therapy regimen versus classical fractionation in the treatment of breast cancer: A randomized study of 230 patients
14. Randomized clinical trial of breast cancer irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update - Ontario Clinical Oncology Group
15. Randomized controlled trial of conservation therapy for breast cancer: Six-year analysis of the Scottish trial - Scottish Cancer Trials Breast Group
16. Radiotherapy after breast preserving surgery in women with localized breast cancer
17. Sector resection with or without postoperative radiotherapy for stage 1 breast cancer: A randomized trial
18. Pathological findings from the National Surgical Adjuvant Breast Project (Protocol 6): Relation of local breast recurrence to multicentricity
19. Outcome of treatment for ipsilateral tumor recurrence in early-stage breast cancer
20. Application of radiosurgery principles to a target in the breast: A dosimetric study
21. The linear-quadratic formula and progress in fractionated radiotherapy
22. Primary breast irradiation in large-breasted or heavy women: Analysis of cosmetic outcome
23. The doserate effect in human tumor cells
24. Response of human tumor cell lines in vitro to fractionated irradiation
25. Repair capacity and kinetics of human skin during fractionated radiotherapy: Erythema, desquamation, and telangiectasia after 3 and 5 years follow-up
26. Time-dose factors in radiotherapy: A review of the human data
27. Pathophysiology of irradiated skin and breast
28. Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer?
29. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses
30. Massive dose technique in radiation of inoperable carcinoma of the breast
31. Rapid radiotherapy for inoperable carcinoma of the breast
32. A method of preoperative roentgen therapy by high doses, followed by radical operation for carcinoma of the breast (showing survival up to 10 years)
33. The concept and implications of multicentricity in breast carcinoma
34. "Residual" mammary carcinoma following simulated partial mastectomy
35. Perioperative stimulation of residual cancer cells promotes local and distant recurrence of breast cancer
36. Presence of growth-stimulating factor in serum following tumor removal in mice
37. A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer
38. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer
39. Irradiation of the tumor bed alone after lumpectomy in selected patients with early-stage breast cancer treated with breast conserving therapy
40. Brachytherapy as the sole method of breast irradiation in TIS, T1 T2, N0-1 breast cancer
41. Sole brachytherapy of the tumor bed after conserving surgery: A new radiotherapeutic strategy for patients at low risk for relapse
42. Cosmetic evaluation of breast conserving treatment for mammary cancer
43. Initial brachytherapy in the breast conservation approach to breast cancer
44. TGF-beta levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis
45. Isoeffect models and fractionated radiation therapy
46. Cell kinetics in vivo of human breast cancer
47. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure Tpot?
48. Radiotherapy for early breast cancer: Was a comprehensive overview of the clinical trials needed?
49. Optimal two-stage designs for phase II clinical trials